GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alterity Therapeutics ATH.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.30

+13.21%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Alterity Therapeutics — daily ASX:ATH

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Alterity Therapeutics on TradingView ↗
Market value
A$1.92bn
Last close × shares
Volume
64.1k
Shares, 9 Nov 2026

About Alterity Therapeutics

Its shares trade on ASX under the ticker ATH.AX. It has been listed since 27 March 2000. In the fiscal year to 30 June 2025, it reported revenue of A$446,300 and a net loss of A$12.1m.

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-03-27. The firm is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The firm's lead product candidates are PBT2 and PBT434. The firm's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The firm also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Figures and description from our data supplier, not checked against the company's own report.

More about Alterity Therapeutics →

Latest on Alterity Therapeutics

Our reporting

We have not reported on Alterity Therapeutics yet.

Next results

4 Mar 2027

Due on 4 Mar 2027. Analysts expect earnings of -0.00 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Alterity Therapeutics's ticker?

Alterity Therapeutics trades as ATH.AX on ASX, under ISIN AU0000043945.

What was Alterity Therapeutics's last closing price?

0.30 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Alterity Therapeutics next report results?

Results are expected on 4 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.